trending Market Intelligence /marketintelligence/en/news-insights/trending/A6WuRUVKjU86sRGDCAOsjA2 content esgSubNav
In This List

Tvardi Therapeutics names CEO

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Tvardi Therapeutics names CEO

Tvardi Therapeutics Inc. said it appointed Imran Alibhai as the company's CEO and board member, effective immediately.

Previously, Alibhai served as senior vice president and managing director at DNAtrix Inc. He was also an investment banker in PJ Solomon LP's healthcare advisory group. In addition, he held investing roles at Accelerator Corp., Alexandria Venture Investments LLC and MPM Capital.

Houston-based Tvardi Therapeutics is a biotechnology company that develops medicines for the treatment of cancer, chronic inflammation and fibrosis.